GuidelineBlood advances2020
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Guideline in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06529042 (Prediction of Adverse Outcomes in Pregnancies of Individuals With Sickle Cell Disease - SCRIPT), which is not on this map. Cited by 229 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of Adverse Outcomes in Pregnancies of Individuals With Sickle Cell Disease - SCRIPT: Sickle Cell Risk in Pregnancy Tool
Who cites it
229 citing papers in PubMed, 7 syntheses or guidelines pooled it, 433 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Hematological Profile in Sickle Cell Disease: A Systematic Review and Meta-Analysis Comparing Steady-State and Vaso-Occlusive Crisis Phases (2000-2025).BioMed research international · 2026Pooled it
- [Guideline for transfusion management in Chinese children with transfusion-dependent thalassemia (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Guideline
- Position statement on the management of pregnancy in sickle cell disease.The Australian & New Zealand journal of obstetrics & gynaecology · 2025Guideline
- Red cell specifications for blood group matching in patients with haemoglobinopathies: An updated systematic review and clinical practice guideline from the International Collaboration for Transfusion Medicine Guidelines.British journal of haematology · 2025Pooled it
- HLA Class II regulation of immune response in sickle cell disease patients: Susceptibility to red blood cell alloimmunization (systematic review and meta-analysis).Vox sanguinis · 2022Pooled it
- Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.Orphanet journal of rare diseases · 2021Pooled it
- Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden.Transfusion · 2025Trial
- Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial.Blood advances · 2024Trial
- Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.Blood advances · 2023Trial
- Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.Acta haematologica · 2023Trial
- Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial.Blood advances · 2021Trial
- Article
- EHA Guidelines on the management of children and adults with hemoglobin SC disease.HemaSphere · 2026Article
- Evaluating Reproductive Health Recommendations in CPGs for Sickle Cell Disease: An Umbrella Review.Clinical and public health guidelines · 2026Article
- Impact of hematologic disorders on decline in hemoglobin levels after total hip arthroplasty.The Journal of international medical research · 2026Article
- ASH clinical practice guidelines: evaluation of discordance between certainty of evidence and strength of recommendations.Blood advances · 2026Article
- Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease.Antibodies (Basel, Switzerland) · 2026Review
- Systemic barriers to donation for African, Caribbean and Black communities: A qualitative key informant study.Transfusion medicine (Oxford, England) · 2026Article
- A Personalized, Rate-of-Rise (ROR)-Driven Model to Optimize Red Cell Exchange Interval in Chronic Sickle Cell Management.Journal of clinical apheresis · 2026Article
169 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 4 countries.
Funding
Abstract
backgroundRed cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes.
objectiveOur objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications.
methodsThe American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment.
resultsThe panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload.
conclusionsThe majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.